Home > Publications database > Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents. > print

001     302329
005     20250630113838.0
024 7 _ |a 10.3390/ph18060906
|2 doi
024 7 _ |a pmid:40573302
|2 pmid
037 _ _ |a DKFZ-2025-01324
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Hennrich, Ute
|0 P:(DE-He78)cf082215dd3b3a42943d2dfe2e22ec20
|b 0
|e First author
|u dkfz
245 _ _ |a Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.
260 _ _ |a Basel
|c 2025
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1751273323_21306
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:W630#LA:E270#
520 _ _ |a Locametz®/Illuccix®/GozellixTM (Novartis AG (Basel, Switzerland) and Telix Pharmaceuticals, Ltd. (Melbourne, Australia), all three [68Ga]Ga-PSMA-11), Pylarify®/Pylclari® (Progenics Pharmaceuticals, Inc. (New York, USA) and Curium PET France SA (Paris, France), both [18F]DCFPyL), Radelumin® (ABX GmbH (Radeberg, Germany), [18F]PSMA-1007), and Posluma® (Blue Earth Diagnostics, Ltd. (Oxford, UK), [18F]rhPSMA-7.3) are four approved PSMA-PET imaging agents that have significantly advanced the diagnosis and management of prostate cancer. These agents offer a new level of precision and accuracy, enabling clinicians to detect prostate cancer with enhanced sensitivity. As a result, they play a critical role in improving detection, staging, and management, ultimately enhancing clinical outcomes for patients. Their use in routine clinical practice is expected to increase diagnostic precision and provide clearer pathways for personalized therapy. This review offers a comprehensive chemical, pharmaceutical, and medicinal overview, discusses comparative studies, and highlights additional highly relevant candidates for prostate cancer detection.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a EMA approval
|2 Other
650 _ 7 |a FDA approval
|2 Other
650 _ 7 |a GozellixTM
|2 Other
650 _ 7 |a Illuccix®
|2 Other
650 _ 7 |a Locametz®
|2 Other
650 _ 7 |a PET diagnostics
|2 Other
650 _ 7 |a PSMA
|2 Other
650 _ 7 |a Posluma®
|2 Other
650 _ 7 |a Pylarify®
|2 Other
650 _ 7 |a Pylclari®
|2 Other
650 _ 7 |a Radelumin®
|2 Other
650 _ 7 |a fluorine-18
|2 Other
650 _ 7 |a gallium-68
|2 Other
650 _ 7 |a prostate cancer
|2 Other
700 1 _ |a Wagner, Laurène
|0 P:(DE-He78)f4cac9f609a993052af693b0acbae449
|b 1
|u dkfz
700 1 _ |a Tas, Harun
|0 P:(DE-He78)857dc4f13329fd151170f3e2b9edfba0
|b 2
|u dkfz
700 1 _ |a Kovacs, Luciana
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Benesova-Schäfer, Martina
|0 P:(DE-He78)0f034e05cefb010f991ef8b96009d95c
|b 4
|e Last author
|u dkfz
773 _ _ |a 10.3390/ph18060906
|g Vol. 18, no. 6, p. 906 -
|0 PERI:(DE-600)2193542-7
|n 6
|p 906
|t Pharmaceuticals
|v 18
|y 2025
|x 1424-8247
909 C O |o oai:inrepo02.dkfz.de:302329
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)cf082215dd3b3a42943d2dfe2e22ec20
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)f4cac9f609a993052af693b0acbae449
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)857dc4f13329fd151170f3e2b9edfba0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)0f034e05cefb010f991ef8b96009d95c
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PHARMACEUTICALS-BASE : 2022
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:30:02Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:30:02Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:30:02Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-04-10T15:30:02Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-28
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-28
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-28
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-28
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-28
920 2 _ |0 I:(DE-He78)E270-20160331
|k E270
|l Translationale Radiotheranostik
|x 0
920 1 _ |0 I:(DE-He78)W630-20160331
|k W630
|l Radiopharmazeutika und Präklinische Studien
|x 0
920 1 _ |0 I:(DE-He78)E270-20160331
|k E270
|l Translationale Radiotheranostik
|x 1
920 0 _ |0 I:(DE-He78)W630-20160331
|k W630
|l Radiopharmazeutika und Präklinische Studien
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)W630-20160331
980 _ _ |a I:(DE-He78)E270-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21